VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Deutsche Boerse AG vs Eli Lilly and Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Deutsche Boerse AG
DB1 · Xetra
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Deutsche Boerse AG's moat claims, evidence, and risks.
View DB1 analysisEli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisComparison highlights
- Moat score gap: Deutsche Boerse AG leads (81 / 100 vs 66 / 100 for Eli Lilly and Company).
- Segment focus: Deutsche Boerse AG has 8 segments (28.2% in Securities Services (Clearstream: ICSD/CSD settlement + custody)); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
- Primary market structure: Duopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Deutsche Boerse AG has 12 moat types across 5 domains; Eli Lilly and Company has 5 across 2.
Primary market context
Deutsche Boerse AG
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Securities settlement and custody infrastructure (ICSD/CSD) for Eurobonds and domestic markets
Global (Eurobonds + multiple domestic markets)
Custodian banks, broker-dealers, central banks, institutional investors
Settlement/custody infrastructure and asset servicing
28.2%
Eli Lilly and Company
Cardiometabolic Health
Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)
Global
Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels
Drug developer, manufacturer, and marketer
65.5%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Deutsche Boerse AG strengths
Eli Lilly and Company strengths
Segment mix
Deutsche Boerse AG segments
Full profile >Financial Derivatives (Eurex trading + Eurex Clearing)
Oligopoly
Commodities (EEX marketplaces + clearing)
Oligopoly
Cash Equities (Xetra + Boerse Frankfurt)
Quasi-Monopoly
FX & Digital Assets (360T + Crypto Finance)
Competitive
Securities Services (Clearstream: ICSD/CSD settlement + custody)
Duopoly
Fund Services (Vestima fund processing + Fund Centre distribution)
Oligopoly
Software Solutions (SimCorp + Axioma Analytics)
Competitive
ESG & Index (ISS STOXX: indices + ESG/governance data)
Oligopoly
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Competitive
Neuroscience
Competitive
Other
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.